Published 1 day ago • loading... • Updated 1 day ago

Orthocell Secures Approval to sell Remplir™ to the U.S. Department of Defence Hospital Network

On Thursday, April 16, 2026, Orthocell Limited secured approval for its Remplir nerve repair device across 51 United States Department of Defence military hospitals and 170 Veterans Affairs medical centres.
Clinical results from 23 surgical procedures on injured soldiers in Ukraine demonstrated Remplir's suitability for treating major traumatic injuries commonly encountered in military settings, validating the device's real-world performance.
Orthocell's existing distributor network covering 17 states will target surgeons within these hospital systems, building on 32 Value Analysis Committee approvals providing access to over 115 hospitals.
Orthocell Managing Director Paul Anderson called the expansion a "significant milestone" for the company's U.S. commercial strategy, enabling direct engagement with military and VA surgeons treating complex nerve injuries.
The company continues to pursue opportunities to increase Remplir utilization across key United States healthcare segments, with 57 Value Analysis Committee applications currently pending approval for further expansion.

Insights by Ground AI

35 Articles

Bennington Banner

+34 Reposted by 34 other sources

Center

Orthocell Secures Approval to sell Remplir™ to the U.S. Department of Defence Hospital Network

Orthocell receives approval for Remplir™ to be used across the United States Department of Defence (DoD) and Veterans Affairs (VA) hospital networks, comprising:51 DoD military hospitals; and170 Veterans Affairs (VA) medical centresFor context, Orthocell has already secured 32 Value Analysis…

1 day ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year